BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 30811471)

  • 1. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
    Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
    PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Idylla
    Makutani Y; Sakai K; Yamada M; Wada T; Chikugo T; Satou T; Iwasa Y; Yamamoto H; de Velasco MA; Nishio K; Kawamura J
    Int J Clin Oncol; 2022 Jul; 27(7):1180-1187. PubMed ID: 35474548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.
    Prieto-Potin I; Montagut C; Bellosillo B; Evans M; Smith M; Melchior L; Reiltin W; Bennett M; Pennati V; Castiglione F; Bürrig KF; Cooper U; Dockhorn-Dworniczak B; Rossenbach C; Luna-Aguirre CM; Barrera-Saldaña HA; Machado JC; Costa JL; Yacobi R; Tabibian-Keissar H; Buglioni S; Ronchetti L; Douglas-Berger L; Dubbink HJ; Alorini M; Sabourin JC; Rojo F
    J Mol Diagn; 2018 Sep; 20(5):664-676. PubMed ID: 29959022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
    Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
    J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing.
    Al-Turkmani MR; Godwin KN; Peterson JD; Tsongalis GJ
    J Appl Lab Med; 2018 Sep; 3(2):178-184. PubMed ID: 33636938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
    Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
    Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
    Zekri J; Baghdadi MA; Alardati H; Khallaf H; Kabanja JH
    Exp Mol Pathol; 2019 Oct; 110():104270. PubMed ID: 31207216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC.
    Colling R; Wang LM; Soilleux E
    J Clin Pathol; 2017 Jul; 70(7):610-614. PubMed ID: 28292978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer.
    Tsongalis GJ; Al Turkmani MR; Suriawinata M; Babcock MJ; Mitchell K; Ding Y; Scicchitano L; Tira A; Buckingham L; Atkinson S; Lax A; Aisner DL; Davies KD; Wood HN; O'Neill SS; Levine EA; Sequeira J; Harada S; DeFrank G; Paluri R; Tan BA; Colabella H; Snead C; Cruz-Correa M; Ramirez V; Rojas A; Huang H; Mackinnon AC; Garcia FU; Cavone SM; Elfahal M; Abel G; Vasef MA; Judd A; Linder MW; Alkhateeb K; Skinner WL; Boccia R; Patel K
    Am J Clin Pathol; 2020 Jul; 154(2):266-276. PubMed ID: 32525522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.